Estrogen-receptor-negative
breast cancer (BCER-) is mainly treated with chemotherapeutics.
Leptin signaling can influence BCER- progression, but its effects on patient survival and chemoresistance are not well understood. We hypothesize that
leptin signaling decreases the survival of BCER- patients by, in part, inducing the expression of chemoresistance-related genes. The correlation of expression of
leptin receptor (OBR),
leptin-targeted genes (CDK8, NANOG, and RBP-Jk), and
breast cancer (BC) patient survival was determined from The
Cancer Genome Atlas (TCGA)
mRNA data.
Leptin-induced expression of proliferation and chemoresistance-related molecules was investigated in triple-negative BC (TNBC) cells that respond differently to chemotherapeutics.
Leptin-induced gene expression in TNBC was analyzed by
RNA-Seq. The specificity of
leptin effects was assessed using OBR inhibitors (
shRNA and
peptides). The results show that OBR and
leptin-targeted gene expression are associated with lower survival of BCER- patients. Importantly, the co-expression of these genes was also associated with
chemotherapy failure.
Leptin signaling increased the expression of
tumorigenesis and chemoresistance-related genes (ABCB1, WNT4, ADHFE1, TBC1D3, LL22NC03, RDH5, and ITGB3) and impaired chemotherapeutic effects in TNBC cells. OBR inhibition re-sensitized TNBC to chemotherapeutics. In conclusion, the co-expression of OBR and
leptin-targeted genes may be used as a predictor of survival and drug resistance of BCER- patients. Targeting OBR signaling could improve chemotherapeutic efficacy.